Ferroptosis inducer-13
Ferroptosis inducer-13 is a 5′-prenylated chalcone derivative that effectively induces ferroptosis in human non-small cell lung cancer (NSCLC) cells by altering the activity of the Nrf2/xCT/GPX4 pathway. Ferroptosis inducer-13 exhibits potent anti-proliferative effects in vitro, and inhibits tumour growth in a NSCLC mouse model. Ferroptosis inducer-13 can be used for NSCLC research.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 3085517-19-4
- 화학식: C21H23NO3
- 분자량:337.41
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
IC50 & Target
[1]|
GPX4 |
In Vitro
Ferroptosis inducer-13 (compound 4a) (72 h) exhibits potent broad-spectrum antiproliferative activity against cancer cells, with IC50 values of 2.11 μM (PC9), 2.17 μM (MDA-MB-231), 3.81 μM (SMMC-7721), and 4.10 μM (SGC-7901)[1].
Ferroptosis inducer-13 (0-40 μM; 24-72 h) exhibits significant anti-proliferative effects on NSCLC cells (PC9 and H1975) in a time- and concentration-dependent manner[1].
Ferroptosis inducer-13 (20 μM; 24 h) induces ferroptosis in NSCLC cells (PC9 and H1975)[1].
Ferroptosis inducer-13 (0-40 μM; 24 h) leads to GSH depletion and increases Fe2+, ROS and LPO levels, and induces ferroptosis through modulation of the Nrf2/xCT/GPX4 signaling pathway in PC9 and H1975 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:PC9, H1975
-
Concentration:0, 2.5, 5, 10, 20, 40 μM
-
Incubation Time:24, 48, 72 h
-
Result:Gradually decreased cell viability of PC9 and H1975 cells in a concentration manner.
Exhibited significant anti-proliferative effects on NSCLC cells (PC9 and H1975) in a time- and concentration-dependent manner.
-
Cell Line:PC9, H1975
-
Concentration:20 μM
-
Incubation Time:12 h
-
Result:Significantly enhanced cell viability by approximately 20% when combined with ferroptosis inhibitor.
-
Cell Line:PC9, H1975
-
Concentration:20 μM
-
Incubation Time:24 h
-
Result:Moderately reversed the GPX expression when combined with ferroptosis inhibitor.
-
Cell Line:PC9, H1975
-
Concentration:0, 5, 10, 20, 40 μM
-
Incubation Time:24 h
-
Result:Significantly decreased Nrf2 levels in both cytoplasmic and nuclear fractions while reducing xCT and GPX4 expression.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female Balb/c nude mice (16-20 g) subcutaneously injected with PC9 cells[1]
-
Dosage:2, 5 mg/kg
-
Administration:i.p.; every 3 days for 18 days
-
Result:Exhibited tumor growth suppression with minimal impact on body weight.
Caused no significant organ toxicity in mice.
Significantly downregulated the protein expression of xCT and GPX4 in tumor tissues compared with the control group.
Chemical Information
-
CAS No. 3085517-19-4
-
분자량 337.41
-
화학식 C21H23NO3
-
SMILES
COC1=CC(OC)=C(C=C1C(/C=C/C2=NC=CC=C2)=O)C/C=C(C)\C
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)